OncoMatch/Clinical Trials/NCT07452198
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07452198 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including GR1803 and Daratumumab for multiple myeloma.
Treatment: GR1803 · Daratumumab · Pomalidomide · Dexamethasone — The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide
Must have received: immunomodulatory drug (lenalidomide)
Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide
Cannot have received: B cell maturation antigen (BCMA)-directed therapy
Received any prior B cell maturation antigen (BCMA)-directed therapy.
Cannot have received: anti-CD38 therapy
Exception: disease that is considered refractory or intolerant to an anti-cluster of differentiation 38 (CD38) targeted therapy
Has disease that is considered refractory or intolerant to an anti-cluster of differentiation 38 (CD38) targeted therapy
Cannot have received: pomalidomide (pomalidomide)
Exception: disease that is considered refractory or intolerant to Pomalidomide
Has disease that is considered refractory or intolerant to ... Pomalidomide
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07452198 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B cell maturation antigen (BCMA)-directed therapy, anti-CD38 therapy, pomalidomide disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages